Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential
Standard
Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential. / Hamley, Madeleine; Leyk, Stephanie; Casar, Christian; Liebold, Imke; Jawazneh, Amirah Al; Lanzloth, Clarissa; Böttcher, Marius; Haas, Helmut; Richardt, Ulricke; Rothlin, Carla V; Jacobs, Thomas; Huber, Samuel; Adlung, Lorenz; Pelczar, Penelope; Henao-Mejia, Jorge; Bosurgi, Lidia.
in: EUR J IMMUNOL, Jahrgang 54, Nr. 2, 02.2024, S. e2350434.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential
AU - Hamley, Madeleine
AU - Leyk, Stephanie
AU - Casar, Christian
AU - Liebold, Imke
AU - Jawazneh, Amirah Al
AU - Lanzloth, Clarissa
AU - Böttcher, Marius
AU - Haas, Helmut
AU - Richardt, Ulricke
AU - Rothlin, Carla V
AU - Jacobs, Thomas
AU - Huber, Samuel
AU - Adlung, Lorenz
AU - Pelczar, Penelope
AU - Henao-Mejia, Jorge
AU - Bosurgi, Lidia
N1 - © 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
PY - 2024/2
Y1 - 2024/2
N2 - The initiation of tissue remodeling following damage is a critical step in preventing the development of immune-mediated diseases. Several factors contribute to mucosal healing, leading to innovative therapeutic approaches for managing intestinal disorders. However, uncovering alternative targets and gaining mechanistic insights are imperative to enhance therapy efficacy and broaden its applicability across different intestinal diseases. Here we demonstrate that Nmes1, encoding for Normal Mucosa of Esophagus-Specific gene 1, also known as Aa467197, is a novel regulator of mucosal healing. Nmes1 influences the macrophage response to the tissue remodeling cytokine IL-4 in vitro. In addition, using two murine models of intestinal damage, each characterized by a type 2-dominated environment with contrasting functions, the ablation of Nmes1 results in decreased intestinal regeneration during the recovery phase of colitis, while enhancing parasitic egg clearance and reducing fibrosis during the advanced stages of Schistosoma mansoni infection. These outcomes are associated with alterations in CX3CR1+ macrophages, cells known for their wound-healing potential in the inflamed colon, hence promising candidates for cell therapies. All in all, our data indicate Nmes1 as a novel contributor to mucosal healing, setting the basis for further investigation into its potential as a new target for the treatment of colon-associated inflammation.
AB - The initiation of tissue remodeling following damage is a critical step in preventing the development of immune-mediated diseases. Several factors contribute to mucosal healing, leading to innovative therapeutic approaches for managing intestinal disorders. However, uncovering alternative targets and gaining mechanistic insights are imperative to enhance therapy efficacy and broaden its applicability across different intestinal diseases. Here we demonstrate that Nmes1, encoding for Normal Mucosa of Esophagus-Specific gene 1, also known as Aa467197, is a novel regulator of mucosal healing. Nmes1 influences the macrophage response to the tissue remodeling cytokine IL-4 in vitro. In addition, using two murine models of intestinal damage, each characterized by a type 2-dominated environment with contrasting functions, the ablation of Nmes1 results in decreased intestinal regeneration during the recovery phase of colitis, while enhancing parasitic egg clearance and reducing fibrosis during the advanced stages of Schistosoma mansoni infection. These outcomes are associated with alterations in CX3CR1+ macrophages, cells known for their wound-healing potential in the inflamed colon, hence promising candidates for cell therapies. All in all, our data indicate Nmes1 as a novel contributor to mucosal healing, setting the basis for further investigation into its potential as a new target for the treatment of colon-associated inflammation.
U2 - 10.1002/eji.202350434
DO - 10.1002/eji.202350434
M3 - SCORING: Journal article
C2 - 37971166
VL - 54
SP - e2350434
JO - EUR J IMMUNOL
JF - EUR J IMMUNOL
SN - 0014-2980
IS - 2
ER -